We are live on ! Find out more

Vir Biotechnology

VIR

Market cap $2.09B

12.21 USD

+1.19

10.8%

At close Updated Nov 6, 4:00 PM EST

Pre-market

After hours

12.32

+0.11

0.9%

1 day

10.8%

5 days

7.48%

1 month

5.26%

3 months

39.22%

6 months

18.66%

Year to date

105.56%

1 year

138.48%

5 years

-62.48%

10 years

-12.91%

About: Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.

Employees: 367

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 17.6%

Neutral 76.5%

Negative 5.9%

Vir Biotechnology to Present Topline Phase 3 ECLIPSE 1 Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta at AASLD's The Liver Meeting® 2026 and Host Investor Conference Call

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from the pivotal Phase 3 ECLIPSE 1 trial evaluating the combination of elebsiran and tobevibart for chronic hepatitis delta in a late-breaking oral presentation at the upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2026 in Denver, CO, November 5-9, 2026. Primary endpoint results of ECLIPSE 1: A randomized open-label Phase 3 study evaluatin.

Vir Biotechnology to Present Topline Phase 3 ECLIPSE 1 Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta at AASLD's The Liver Meeting® 2026 and Host Investor Conference Call

What Vir Biotechnology (VIR) Said on Its Q3 Earnings Call

Vir Biotechnology NASDAQ: VIR expects to report the first phase 3 results for its experimental hepatitis delta treatment in the fourth quarter of 2026, with data from two additional studies due in the first quarter of 2027, executives said on the company's third-quarter earnings call.

What Vir Biotechnology (VIR) Said on Its Q3 Earnings Call

Vir Biotechnology, Inc. (VIR) Q3 2026 Earnings Call Transcript

Vir Biotechnology, Inc. (VIR) Q3 2026 Earnings Call Transcript

Vir Biotechnology, Inc. (VIR) Q3 2026 Earnings Call Transcript

Zacks Investment Research

Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Misses Revenue Estimates

Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.8. This compares to a loss of $1.17 per share a year ago.

Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Misses Revenue Estimates

Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2026 Financial Results

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the third quarter ended September 30, 2026. “We are entering an important period for Vir Bio, with meaningful catalysts across both hepatitis delta and oncology,” said Marianne De Backer, President and Chief Executive Officer of Vir Biotechnology. “We look forward to reporting topline ECLIPSE 1 data this quarter as we advance our goal to address the signifi.

Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2026 Financial Results

Vir Biotechnology to Participate in the Jefferies 2026 London Healthcare Conference

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, President and Chief Executive Officer, will present at the Jefferies 2026 London Healthcare Conference on Wednesday, November 18 at 10:30 a.m. GMT / 5:30 a.m. ET in London, United Kingdom.A live webcast of the fireside chat will be available at https://investors.vir.bio and will be archived for 30 days.About Vir BiotechnologyVir Biotechnology, Inc. is a clinical-stag.

Vir Biotechnology to Participate in the Jefferies 2026 London Healthcare Conference

Vir Biotechnology Announces Appointment of Suzanne Topalian to its Board of Directors

SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced the appointment of Suzanne Topalian, M.D., to its Board of Directors, effective October 27, 2026. Dr. Topalian is the Bloomberg-Kimmel Professor of Cancer Immunotherapy at the Johns Hopkins University School of Medicine* and serves as Associate Director of the Bloomberg-Kimmel Institute for Cancer Immunotherapy and Director Melanoma/Skin Cancer Program in the Kimmel Cancer Center at Johns Hopkins. “Su.

Vir Biotechnology Announces Appointment of Suzanne Topalian to its Board of Directors

Vir Biotechnology: A Big Pharma Collaboration And 2 Clinical Catalysts This Quarter

VIR's PRO-XTEN platform has attracted major pharma collaborations, validating its dual-masked T-cell engager technology for oncology and solid tumors. Near-term catalysts include ECLIPSE program readouts for hepatitis delta (Q4'26/Q1'27) and VIR-5818 oncology data, with positive outcomes likely based on prior results. VIR's competitors in hepatitis delta include GILD and MIRM, but VIR's prior data suggests exceptional efficacy in hepatitis delta, which may differentiate its therapeutic.

Vir Biotechnology: A Big Pharma Collaboration And 2 Clinical Catalysts This Quarter

Vir Biotechnology to Host Conference Call for Third Quarter 2026 Financial Results

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, November 4 to provide a corporate update and discuss its financial results for the third quarter ended September 30, 2026. The conference call may be accessed on the Events & Presentations page of the Vir Biotechnology website. About Vir Biotechnology Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focus.

Vir Biotechnology to Host Conference Call for Third Quarter 2026 Financial Results

Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments

Vir Biotechnology Inc. (NASDAQ:VIR) announced a major collaboration with Gilead Sciences Inc. (NASDAQ:GILD) to create three novel T-cell engagers (TCEs) aimed at treating solid tumors.

Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments

See News Rankings

Price charts implemented using Lightweight Charts™